420 participants enrolled, randomized and vaccinated (TVC)

QIV group (N=105)
- Per-protocol cohort for Immunogenicity (N=104)
  - 1 participant excluded - non-compliance with the blood sampling schedule
  - 105 completed study

LD QIV-AS group (N=105)
- Per-protocol cohort for Immunogenicity (N=104)
  - 1 participant excluded - Essential serological data missing
  - 102 completed study

LD TIV-AS group (N=105)
- Per-protocol cohort for Immunogenicity (N=104)
  - 1 participant excluded - Non-compliance with the blood sampling schedule
  - 105 completed study

TIV group (N=105)
- Per-protocol cohort for Immunogenicity (N=105)
  - 1 participant lost to follow-up
  - 104 completed study